

# Olli Kallioniemi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3942583/publications.pdf>

Version: 2024-02-01

438  
papers

52,432  
citations

1893

102  
h-index

1505

219  
g-index

460  
all docs

460  
docs citations

460  
times ranked

50887  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tissue microarrays for high-throughput molecular profiling of tumor specimens. <i>Nature Medicine</i> , 1998, 4, 844-847.	30.7	3,661
2	Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies. <i>American Journal of Human Genetics</i> , 2003, 72, 1117-1130.	6.2	3,105
3	Comparative Genomic Hybridization for Molecular Cytogenetic Analysis of Solid Tumors. <i>Science</i> , 1992, 258, 818-821.	12.6	3,065
4	International network of cancer genome projects. <i>Nature</i> , 2010, 464, 993-998.	27.8	2,114
5	Gene-Expression Profiles in Hereditary Breast Cancer. <i>New England Journal of Medicine</i> , 2001, 344, 539-548.	27.0	1,669
6	High frequency of BRAF mutations in nevi. <i>Nature Genetics</i> , 2003, 33, 19-20.	21.4	1,547
7	ALB1, a Steroid Receptor Coactivator Amplified in Breast and Ovarian Cancer. <i>Science</i> , 1997, 277, 965-968.	12.6	1,514
8	In vivo amplification of the androgen receptor gene and progression of human prostate cancer. <i>Nature Genetics</i> , 1995, 9, 401-406.	21.4	1,316
9	Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. <i>Genes Chromosomes and Cancer</i> , 1994, 10, 231-243.	2.8	1,215
10	Major Susceptibility Locus for Prostate Cancer on Chromosome 1 Suggested by a Genome-Wide Search. <i>Science</i> , 1996, 274, 1371-1374.	12.6	717
11	Somatic <i>STAT3</i> Mutations in Large Granular Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2012, 366, 1905-1913.	27.0	681
12	Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994, 91, 2156-2160.	7.1	661
13	A community effort to assess and improve drug sensitivity prediction algorithms. <i>Nature Biotechnology</i> , 2014, 32, 1202-1212.	17.5	653
14	Evidence for a prostate cancer susceptibility locus on the X chromosome.. <i>Nature Genetics</i> , 1998, 20, 175-179.	21.4	641
15	Tissue Microarrays for Rapid Linking of Molecular Changes to Clinical Endpoints. <i>American Journal of Pathology</i> , 2001, 159, 2249-2256.	3.8	521
16	Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome. <i>American Journal of Pathology</i> , 2002, 161, 1991-1996.	3.8	494
17	ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 5321-5325.	7.1	493
18	Tissue microarray technology for high-throughput molecular profiling of cancer. <i>Human Molecular Genetics</i> , 2001, 10, 657-662.	2.9	479

#	ARTICLE	IF	CITATIONS
19	Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. <i>Nature Genetics</i> , 2002, 30, 181-184.	21.4	470
20	The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. <i>British Journal of Cancer</i> , 2008, 98, 1457-1466.	6.4	461
21	Novel Theranostic Opportunities Offered by Characterization of Altered Membrane Lipid Metabolism in Breast Cancer Progression. <i>Cancer Research</i> , 2011, 71, 3236-3245.	0.9	444
22	Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. <i>Oncogene</i> , 2003, 22, 2021-2033.	5.9	415
23	A CHEK2 Genetic Variant Contributing to a Substantial Fraction of Familial Breast Cancer. <i>American Journal of Human Genetics</i> , 2002, 71, 432-438.	6.2	402
24	MicroRNA in Prostate, Bladder, and Kidney Cancer: A Systematic Review. <i>European Urology</i> , 2011, 59, 671-681.	1.9	401
25	Break-Induced Replication Repair of Damaged Forks Induces Genomic Duplications in Human Cells. <i>Science</i> , 2014, 343, 88-91.	12.6	387
26	High-Throughput Tissue Microarray Analysis to Evaluate Genes Uncovered by cDNA Microarray Screening in Renal Cell Carcinoma. <i>American Journal of Pathology</i> , 1999, 154, 981-986.	3.8	376
27	Association of <i>erbB2</i> protein overexpression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. <i>International Journal of Cancer</i> , 1991, 49, 650-655.	5.1	352
28	Association of Overexpression of Tumor Suppressor Protein p53 With Rapid Cell Proliferation and Poor Prognosis in Node-Negative Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 1992, 84, 1109-1114.	6.3	337
29	Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2013, 3, 1416-1429.	9.4	334
30	Hormone Therapy Failure in Human Prostate Cancer: Analysis by Complementary DNA and Tissue Microarrays. <i>Journal of the National Cancer Institute</i> , 1999, 91, 1758-1764.	6.3	325
31	Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. <i>EMBO Journal</i> , 2011, 30, 3962-3976.	7.8	318
32	The impact of low-frequency and rare variants on lipid levels. <i>Nature Genetics</i> , 2015, 47, 589-597.	21.4	310
33	Identification of fusion genes in breast cancer by paired-end RNA-sequencing. <i>Genome Biology</i> , 2011, 12, R6.	9.6	301
34	Small Subgroup of Aggressive, Highly Proliferative Prostatic Carcinomas Defined by p53 Accumulation. <i>Journal of the National Cancer Institute</i> , 1992, 84, 883-887.	6.3	299
35	A Comprehensive Panel of Three-Dimensional Models for Studies of Prostate Cancer Growth, Invasion and Drug Responses. <i>PLoS ONE</i> , 2010, 5, e10431.	2.5	299
36	miRNA-mRNA Integrated Analysis Reveals Roles for miRNAs in Primary Breast Tumors. <i>PLoS ONE</i> , 2011, 6, e16915.	2.5	278

#	ARTICLE	IF	CITATIONS
37	Emerging molecular biomarkers—blood-based strategies to detect and monitor cancer. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 142-150.	27.6	277
38	Genome screening by comparative genomic hybridization. <i>Trends in Genetics</i> , 1997, 13, 405-409.	6.7	272
39	Positional cloning of <i>ZNF217</i> and <i>NABC1</i> : Genes amplified at 20q13.2 and overexpressed in breast carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 8703-8708.	7.1	271
40	Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. <i>Blood</i> , 2013, 121, 4541-4550.	1.4	252
41	Detecting Activation of Ribosomal Protein S6 Kinase by Complementary DNA and Tissue Microarray Analysis. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1252-1259.	6.3	251
42	Computer image analysis of comparative genomic hybridization. <i>Cytometry</i> , 1995, 19, 10-26.	1.8	250
43	Systematic Analysis of MicroRNAs Targeting the Androgen Receptor in Prostate Cancer Cells. <i>Cancer Research</i> , 2011, 71, 1956-1967.	0.9	244
44	Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. <i>Scientific Reports</i> , 2014, 4, 5193.	3.3	243
45	Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction: A proposed classification of DNA histograms in breast cancer. <i>Cancer</i> , 1988, 62, 2183-2190.	4.1	240
46	Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and pathological tissues. <i>Genome Biology</i> , 2008, 9, R139.	9.6	234
47	High-Throughput Tissue Microarray Analysis of Cyclin E Gene Amplification and Overexpression in Urinary Bladder Cancer. <i>American Journal of Pathology</i> , 2000, 157, 787-794.	3.8	232
48	ProteomeBinders: planning a European resource of affinity reagents for analysis of the human proteome. <i>Nature Methods</i> , 2007, 4, 13-17.	19.0	231
49	<i>FZD4</i> as a Mediator of <i>ERG</i> Oncogene-Induced WNT Signaling and Epithelial-to-Mesenchymal Transition in Human Prostate Cancer Cells. <i>Cancer Research</i> , 2010, 70, 6735-6745.	0.9	229
50	Comparison of fresh and paraffin-embedded tissue as starting material for DNA flow cytometry and evaluation of intratumor heterogeneity. <i>Cytometry</i> , 1988, 9, 164-169.	1.8	228
51	Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 421-430.	2.5	222
52	Tissue microarrays (TMAs) for high-throughput molecular pathology research. <i>International Journal of Cancer</i> , 2001, 94, 1-5.	5.1	220
53	TMPRSS2 Fusions with Oncogenic ETS Factors in Prostate Cancer Involve Unbalanced Genomic Rearrangements and Are Associated with HDAC1 and Epigenetic Reprogramming. <i>Cancer Research</i> , 2006, 66, 10242-10246.	0.9	209
54	SATB2 in Combination With Cytokeratin 20 Identifies Over 95% of all Colorectal Carcinomas. <i>American Journal of Surgical Pathology</i> , 2011, 35, 937-948.	3.7	209

#	ARTICLE	IF	CITATIONS
55	Axitinib effectively inhibits BCR-ABL1 (T315I) with a distinct binding conformation. <i>Nature</i> , 2015, 519, 102-105.	27.8	207
56	CIP2A Is Associated with Human Breast Cancer Aggressivity. <i>Clinical Cancer Research</i> , 2009, 15, 5092-5100.	7.0	205
57	Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. <i>Oncogene</i> , 2009, 28, 3926-3936.	5.9	205
58	Inferring Tree Models for Oncogenesis from Comparative Genome Hybridization Data. <i>Journal of Computational Biology</i> , 1999, 6, 37-51.	1.6	202
59	Germline Alterations of the RNASEL Gene, a Candidate HPC1 Gene at 1q25, in Patients and Families with Prostate Cancer. <i>American Journal of Human Genetics</i> , 2002, 70, 1299-1304.	6.2	202
60	Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization. <i>Genes Chromosomes and Cancer</i> , 1995, 12, 213-219.	2.8	198
61	Prognostic significance of dna index, multiploidy, and S-phase fraction in ovarian cancer. <i>Cancer</i> , 1988, 61, 334-339.	4.1	197
62	Differentiation of Human Embryonal Carcinomas In vitro and In vivo Reveals Expression Profiles Relevant to Normal Development. <i>Cancer Research</i> , 2005, 65, 5588-5598.	0.9	194
63	A Nuclear Factor, ASC-2, as a Cancer-amplified Transcriptional Coactivator Essential for Ligand-dependent Transactivation by Nuclear Receptors in Vivo. <i>Journal of Biological Chemistry</i> , 1999, 274, 34283-34293.	3.4	190
64	Molecular cytogenetic analysis of 11 new breast cancer cell lines. <i>British Journal of Cancer</i> , 1999, 81, 1328-1334.	6.4	186
65	High-Throughput Cell-Based Screening of 4910 Known Drugs and Drug-like Small Molecules Identifies Disulfiram as an Inhibitor of Prostate Cancer Cell Growth. <i>Clinical Cancer Research</i> , 2009, 15, 6070-6078.	7.0	185
66	SHARPIN is an endogenous inhibitor of $\beta$ 1-integrin activation. <i>Nature Cell Biology</i> , 2011, 13, 1315-1324.	10.3	184
67	Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. <i>Nature Genetics</i> , 2004, 36, 979-983.	21.4	180
68	Are data from different gene expression microarray platforms comparable?. <i>Genomics</i> , 2004, 83, 1164-1168.	2.9	179
69	Integrin Trafficking Regulated by Rab21 Is Necessary for Cytokinesis. <i>Developmental Cell</i> , 2008, 15, 371-385.	7.0	177
70	Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies. <i>Clinical Cancer Research</i> , 2018, 24, 794-806.	7.0	177
71	RNAi Microarray Analysis in Cultured Mammalian Cells. <i>Genome Research</i> , 2003, 13, 2341-2347.	5.5	173
72	Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 1062-1069.	2.8	172

#	ARTICLE	IF	CITATIONS
73	Application of Active and Kinase-Deficient Kinome Collection for Identification of Kinases Regulating Hedgehog Signaling. <i>Cell</i> , 2008, 133, 537-548.	28.9	171
74	Evaluation of cell proliferation in breast carcinoma. Comparison of Ki-67 immunohistochemical study, DNA flow cytometric analysis, and mitotic count. <i>Cancer</i> , 1990, 65, 1180-1184.	4.1	169
75	Metabolomic Profiling of Extracellular Vesicles and Alternative Normalization Methods Reveal Enriched Metabolites and Strategies to Study Prostate Cancer-Related Changes. <i>Theranostics</i> , 2017, 7, 3824-3841.	10.0	167
76	Tumour DNA ploidy as an independent prognostic factor in breast cancer. <i>British Journal of Cancer</i> , 1987, 56, 637-642.	6.4	163
77	Population-Based Study of BRCA1 and BRCA2 Mutations in 1035 Unselected Finnish Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1529-1531.	6.3	159
78	Claudin-1 overexpression in melanoma is regulated by PKC and contributes to melanoma cell motility. <i>Oncogene</i> , 2007, 26, 3846-3856.	5.9	155
79	High-Throughput 3D Screening Reveals Differences in Drug Sensitivities between Culture Models of JIMT1 Breast Cancer Cells. <i>PLoS ONE</i> , 2013, 8, e77232.	2.5	154
80	Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 9603-9608.	7.1	153
81	High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. <i>Molecular Oncology</i> , 2014, 8, 93-104.	4.6	146
82	Androgen regulation of microRNAs in prostate cancer. <i>Prostate</i> , 2011, 71, 604-614.	2.3	144
83	Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress. <i>British Journal of Cancer</i> , 2012, 106, 99-106.	6.4	141
84	Aneuploid DNA content and high S-phase fraction of tumour cells are related to poor prognosis in patients with primary breast cancer. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1987, 23, 277-282.	0.7	134
85	ANDROGEN RECEPTOR GENE AMPLIFICATION AT PRIMARY PROGRESSION PREDICTS RESPONSE TO COMBINED ANDROGEN BLOCKADE AS SECOND LINE THERAPY FOR ADVANCED PROSTATE CANCER. <i>Journal of Urology</i> , 2000, 164, 1992-1995.	0.4	134
86	CHEK2 variant I157T may be associated with increased breast cancer risk. <i>International Journal of Cancer</i> , 2004, 111, 543-547.	5.1	134
87	Tissue Microarrays: What Will They Bring to Molecular and Anatomic Pathology?. <i>Advances in Anatomic Pathology</i> , 2001, 8, 14-20.	4.3	133
88	Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. <i>Human Molecular Genetics</i> , 1997, 6, 2309-2315.	2.9	128
89	ANX7, a candidate tumor suppressor gene for prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 4575-4580.	7.1	128
90	MiR-9, -31, and -182 Deregulation Promote Proliferation and Tumor Cell Survival in Colon Cancer. <i>Neoplasia</i> , 2012, 14, 868-IN21.	5.3	124

#	ARTICLE	IF	CITATIONS
91	Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. <i>Oncogene</i> , 2001, 20, 6718-6723.	5.9	122
92	Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. <i>Journal of Medical Genetics</i> , 2005, 42, 602-603.	3.2	121
93	Role of ErbB4 in Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2008, 13, 259-268.	2.7	121
94	Non-canonical Notch signaling activates IL-6/JAK/STAT signaling in breast tumor cells and is controlled by p53 and IKK1±/IKK1². <i>Oncogene</i> , 2013, 32, 4892-4902.	5.9	121
95	Consensus review of the clinical utility of dna content cytometry in prostate cancer. <i>Cytometry</i> , 1993, 14, 497-500.	1.8	120
96	Systems pathology by multiplexed immunohistochemistry and whole-slide digital image analysis. <i>Scientific Reports</i> , 2017, 7, 15580.	3.3	120
97	Improved technique for analysis of formalin-fixed, paraffin-embedded tumors by fluorescence in situ hybridization. <i>Cytometry</i> , 1994, 16, 93-99.	1.8	116
98	Association of tamoxifen resistance and lipid reprogramming in breast cancer. <i>BMC Cancer</i> , 2018, 18, 850.	2.6	113
99	Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion. <i>Oncogene</i> , 2012, 31, 3444-3456.	5.9	112
100	An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. <i>Oncogene</i> , 2012, 31, 2090-2100.	5.9	111
101	Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 1993, 11, 36-43.	1.6	110
102	High-Resolution Analysis of Gene Copy Number Alterations in Human Prostate Cancer Using CGH on cDNA Microarrays: Impact of Copy Number on Gene Expression. <i>Neoplasia</i> , 2004, 6, 240-247.	5.3	110
103	Comparative genomic hybridization reveals frequent gains of 20q, 8q, 11q, 12p, and 17q, and losses of 18q, 9p, and 15q in pancreatic cancer. <i>Genes Chromosomes and Cancer</i> , 1997, 20, 383-391.	2.8	106
104	Arachidonic Acid Pathway Members PLA2G7, HPGD, EPHX2, and CYP4F8 Identified as Putative Novel Therapeutic Targets in Prostate Cancer. <i>American Journal of Pathology</i> , 2011, 178, 525-536.	3.8	102
105	Integrative and Personalized QSAR Analysis in Cancer by Kernelized Bayesian Matrix Factorization. <i>Journal of Chemical Information and Modeling</i> , 2014, 54, 2347-2359.	5.4	101
106	Cloning of <i>BCAS3</i> (17q23) and <i>BCAS4</i> (20q13) genes that undergo amplification, overexpression, and fusion in breast cancerâ€. <i>Genes Chromosomes and Cancer</i> , 2002, 35, 311-317.	2.8	100
107	ElevatederbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. <i>Cancer</i> , 1994, 73, 652-658.	4.1	98
108	Genotyping of Adrenocortical Tumors: Very Frequent Deletions of the MEN1 Locus in 11q13 and of a 1-Centimorgan Region in 2p161. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 730-735.	3.6	97



#	ARTICLE	IF	CITATIONS
109	Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. <i>International Journal of Cancer</i> , 2005, 113, 575-580.	5.1	97
110	Distance-Based Reconstruction of Tree Models for Oncogenesis. <i>Journal of Computational Biology</i> , 2000, 7, 789-803.	1.6	96
111	High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion. <i>Oncotarget</i> , 2013, 4, 48-63.	1.8	95
112	Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2014, 28, 1738-1742.	7.2	90
113	JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. <i>Blood</i> , 2017, 130, 789-802.	1.4	90
114	Identification of target genes in laryngeal squamous cell carcinoma by high-resolution copy number and gene expression microarray analyses. <i>Oncogene</i> , 2006, 25, 6997-7008.	5.9	88
115	Novel Human Vascular Endothelial Growth Factor Genes VEGF-B and VEGF-C Localize to Chromosomes 11q13 and 4q34, Respectively. <i>Circulation</i> , 1996, 93, 1079-1082.	1.6	88
116	Drug response prediction by inferring pathway-response associations with kernelized Bayesian matrix factorization. <i>Bioinformatics</i> , 2016, 32, i455-i463.	4.1	87
117	Hardware and software requirements for quantitative analysis of comparative genomic hybridization. <i>Cytometry</i> , 1995, 19, 4-9.	1.8	86
118	Expression of Bcl-2 Family Member Bid in Normal and Malignant Tissues. <i>Neoplasia</i> , 2002, 4, 129-140.	5.3	82
119	Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading. <i>British Journal of Cancer</i> , 1990, 62, 142-146.	6.4	81
120	EphB2 Expression across 138 Human Tumor Types in a Tissue Microarray: High Levels of Expression in Gastrointestinal Cancers. <i>Clinical Cancer Research</i> , 2005, 11, 6450-6458.	7.0	81
121	Visual Mapping by Fiber-FISH. <i>Genomics</i> , 1995, 30, 31-36.	2.9	80
122	Monensin Is a Potent Inducer of Oxidative Stress and Inhibitor of Androgen Signaling Leading to Apoptosis in Prostate Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 3175-3185.	4.1	80
123	The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells. <i>Molecular Oncology</i> , 2013, 7, 392-401.	4.6	80
124	Biochip technologies in cancer research. <i>Annals of Medicine</i> , 2001, 33, 142-147.	3.8	79
125	The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer. <i>European Journal of Cancer</i> , 2009, 45, 1510-1517.	2.8	79
126	Different opinions on classification of DNA histograms produced from paraffin-embedded tissue. <i>Cytometry</i> , 1989, 10, 711-717.	1.8	77



#	ARTICLE	IF	CITATIONS
127	Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins. <i>Oncotarget</i> , 2011, 2, 1176-1190.	1.8	77
128	Immunohistochemical determination of estrogen and progesterone receptors in human breast carcinoma. Correlation with histopathology and dna flow cytometry. <i>Cancer</i> , 1990, 63, 1761-1767.	4.1	76
129	Consistency in drug response profiling. <i>Nature</i> , 2016, 540, E5-E6.	27.8	76
130	Genotyping of Adrenocortical Tumors: Very Frequent Deletions of the MEN1 Locus in 11q13 and of a 1-Centimorgan Region in 2p16. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 730-735.	3.6	76
131	Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland. <i>European Journal of Human Genetics</i> , 2000, 8, 757-763.	2.8	75
132	Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling. <i>Leukemia</i> , 2018, 32, 774-787.	7.2	75
133	Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML. <i>Leukemia</i> , 2018, 32, 1643-1656.	7.2	75
134	Increased copy number at 17q22-q24 by CGH in breast cancer is due to high-level amplification of two separate regions. , 1997, 20, 372-376.		74
135	Topoisomerase-III± Is Upregulated in Malignant Peripheral Nerve Sheath Tumors and Associated With Clinical Outcome. <i>Journal of Clinical Oncology</i> , 2003, 21, 4586-4591.	1.6	74
136	Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer. <i>European Urology</i> , 2017, 71, 319-327.	1.9	74
137	Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: Correlation with dna flow cytometry, biochemical receptor assay, and patient survival. <i>Journal of Pathology</i> , 1990, 162, 295-301.	4.5	73
138	Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2022, 12, 388-401.	9.4	73
139	Identification of MicroRNAs Inhibiting TGF-Î²-Induced IL-11 Production in Bone Metastatic Breast Cancer Cells. <i>PLoS ONE</i> , 2012, 7, e37361.	2.5	72
140	Reanalysis of RNA-Sequencing Data Reveals Several Additional Fusion Genes with Multiple Isoforms. <i>PLoS ONE</i> , 2012, 7, e48745.	2.5	72
141	Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome. <i>Oncogene</i> , 2004, 23, 2264-2274.	5.9	71
142	Improved prognostic impact of S-phase values from paraffin-embedded breast and prostate carcinomas after correcting for nuclear slicing. <i>Cytometry</i> , 1991, 12, 413-421.	1.8	68
143	c-Jun N-Terminal Kinase Phosphorylation of MARCKSL1 Determines Actin Stability and Migration in Neurons and in Cancer Cells. <i>Molecular and Cellular Biology</i> , 2012, 32, 3513-3526.	2.3	68
144	Integration of Metabolomics and Expression of Glycerol-3-phosphate Acyltransferase (GPAM) in Breast Cancer—Link to Patient Survival, Hormone Receptor Status, and Metabolic Profiling. <i>Journal of Proteome Research</i> , 2012, 11, 850-860.	3.7	68

#	ARTICLE	IF	CITATIONS
145	Breeze: an integrated quality control and data analysis application for high-throughput drug screening. <i>Bioinformatics</i> , 2020, 36, 3602-3604.	4.1	68
146	Quality control of CGH: Impact of metaphase chromosomes and the dynamic range of hybridization. <i>Cytometry</i> , 1997, 28, 198-205.	1.8	66
147	A genomic map of a 6-Mb region at 13q21-q22 implicated in cancer development: identification and characterization of candidate genes. <i>Human Genetics</i> , 2002, 110, 111-121.	3.8	66
148	Serum CA 15-3 assay in the diagnosis and follow-up of breast cancer. <i>British Journal of Cancer</i> , 1988, 58, 213-215.	6.4	64
149	Androgen Receptor Gene Amplification in a Recurrent Prostate Cancer after Monotherapy with the Nonsteroidal Potent Antiandrogen Casodex (Bicalutamide) with a Subsequent Favorable Response to Maximal Androgen Blockade. <i>European Urology</i> , 1997, 31, 216-219.	1.9	64
150	PD-L1 <sup>+</sup> tumor-associated macrophages and PD-1 <sup>+</sup> tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma. <i>Haematologica</i> , 2018, 103, 1908-1914.	3.5	64
151	New Paraoxonase 1 Polymorphism I102V and the Risk of Prostate Cancer in Finnish Men. <i>Journal of the National Cancer Institute</i> , 2003, 95, 812-818.	6.3	62
152	Androgen receptor CAG polymorphism and prostate cancer risk. <i>Human Genetics</i> , 2002, 111, 166-171.	3.8	61
153	Functional evidence implicating S100P in prostate cancer progression. <i>International Journal of Cancer</i> , 2008, 123, 330-339.	5.1	61
154	HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia. <i>Leukemia</i> , 2017, 31, 301-309.	7.2	61
155	Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model. <i>British Journal of Cancer</i> , 1997, 75, 190-195.	6.4	60
156	Novel findings in gene expression detected in human osteosarcoma by cDNA microarray. <i>Cancer Genetics and Cytogenetics</i> , 2000, 123, 128-132.	1.0	60
157	CGH, cDNA and Tissue Microarray Analyses Implicate <i>FGFR2</i> Amplification in a Small Subset of Breast Tumors. <i>Analytical Cellular Pathology</i> , 2001, 22, 229-234.	2.1	60
158	Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG <sup>+</sup> positive prostate cancer. <i>International Journal of Cancer</i> , 2008, 123, 2774-2781.	5.1	60
159	Identification of miR-193b Targets in Breast Cancer Cells and Systems Biological Analysis of Their Functional Impact. <i>Molecular and Cellular Proteomics</i> , 2011, 10, M110.005322.	3.8	60
160	KeepEX, a simple dilution protocol for improving extracellular vesicle yields from urine. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 98, 30-39.	4.0	59
161	Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation. <i>Blood Cancer Journal</i> , 2013, 3, e168-e168.	6.2	56
162	Genetic Basis and Clonal Evolution of Human Prostate Cancer. <i>Advances in Cancer Research</i> , 1996, 68, 225-255.	5.0	55

#	ARTICLE	IF	CITATIONS
163	CHEK2 1100delC is not a risk factor for male breast cancer population. <i>International Journal of Cancer</i> , 2004, 108, 475-476.	5.1	55
164	Profiling Genetic Variation along the Androgen Biosynthesis and Metabolism Pathways Implicates Several Single Nucleotide Polymorphisms and Their Combinations as Prostate Cancer Risk Factors. <i>Cancer Research</i> , 2006, 66, 743-747.	0.9	54
165	High-Throughput Transcriptomic and RNAi Analysis Identifies AIM1, ERGIC1, TMED3 and TPX2 as Potential Drug Targets in Prostate Cancer. <i>PLoS ONE</i> , 2012, 7, e39801.	2.5	54
166	Novel Genomic Aberrations in Testicular Germ Cell Tumors by Array-CGH, and Associated Gene Expression Changes. <i>Analytical Cellular Pathology</i> , 2006, 28, 315-326.	1.4	54
167	Frequent loss of the 11q14-24 region in chronic lymphocytic leukemia: A study by comparative genomic hybridization. , 1997, 19, 286-290.		53
168	Systematic Identification of MicroRNAs That Impact on Proliferation of Prostate Cancer Cells and Display Changed Expression in Tumor Tissue. <i>European Urology</i> , 2016, 69, 1120-1128.	1.9	53
169	Amplification and overexpression of PRUNE in human sarcomas and breast carcinomasâ€“a possible mechanism for altering the nm23-H1 activity. <i>Oncogene</i> , 2001, 20, 6881-6890.	5.9	52
170	Individual and stable autoantibody repertoires in healthy individuals. <i>Autoimmunity</i> , 2019, 52, 1-11.	2.6	52
171	Chapter I. Biology and natural history of breast cancer. <i>International Journal of Cancer</i> , 1990, 46, 5-21.	5.1	51
172	Flow cytometric DNA analysis of 199 histologically favourable or unfavourable non-Hodgkin lymphomas. <i>Journal of Pathology</i> , 1989, 157, 27-36.	4.5	50
173	A physical map of chromosome 20 established using fluorescence in situ hybridization and digital image analysis. <i>Genomics</i> , 1995, 26, 134-137.	2.9	50
174	Somatic genetic alterations inBRCA2-associated and sporadic male breast cancer. <i>Genes Chromosomes and Cancer</i> , 1999, 24, 56-61.	2.8	50
175	A cell spot microarray method for production of high density siRNA transfection microarrays. <i>BMC Genomics</i> , 2011, 12, 162.	2.8	50
176	Flow cytometric analysis of DNA ploidy and S-phase fraction from prostatic carcinomas: implications for prognosis and response to endocrine therapy. <i>British Journal of Cancer</i> , 1991, 64, 578-582.	6.4	49
177	Dietary flavonoid fisetin induces a forced exit from mitosis by targeting the mitotic spindle checkpoint. <i>Carcinogenesis</i> , 2009, 30, 1032-1040.	2.8	49
178	Fibroblast Growth Factor Receptor 4 Regulates Tumor Invasion by Coupling Fibroblast Growth Factor Signaling to Extracellular Matrix Degradation. <i>Cancer Research</i> , 2010, 70, 7851-7861.	0.9	49
179	The gene expression landscape of breast cancer is shaped by tumor protein p53 status and epithelial-mesenchymal transition. <i>Breast Cancer Research</i> , 2012, 14, R113.	5.0	49
180	Functional Screening Identifies miRNAs Influencing Apoptosis and Proliferation in Colorectal Cancer. <i>PLoS ONE</i> , 2014, 9, e96767.	2.5	49

#	ARTICLE	IF	CITATIONS
181	A novel strategy for microarray quality control using Bayesian networks. <i>Bioinformatics</i> , 2003, 19, 2031-2038.	4.1	48
182	Cytokinesis failure due to derailed integrin traffic induces aneuploidy and oncogenic transformation in vitro and in vivo. <i>Oncogene</i> , 2012, 31, 3597-3606.	5.9	48
183	A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland. <i>British Journal of Cancer</i> , 2001, 84, 1344-1347.	6.4	47
184	Genome-wide scan for linkage in finnish hereditary prostate cancer (HPC) families identifies novel susceptibility loci at 11q14 and 3p25-26. <i>Prostate</i> , 2003, 57, 280-289.	2.3	47
185	Cell of Origin Links Histotype Spectrum to Immune Microenvironment Diversity in Non-small-Cell Lung Cancer Driven by Mutant Kras and Loss of Lkb1. <i>Cell Reports</i> , 2017, 18, 673-684.	6.4	47
186	Candidate Genes for Testicular Cancer Evaluated by In Situ Protein Expression Analyses on Tissue Microarrays. <i>Neoplasia</i> , 2003, 5, 397-404.	5.3	46
187	Primary undifferentiated small cell carcinoma of the esophagus: Clinicopathological and flow cytometric evaluation of eight cases. <i>Journal of Surgical Oncology</i> , 1991, 46, 174-177.	1.7	45
188	Gains and losses of DNA sequences in malignant mesothelioma by comparative genomic hybridization. <i>Cancer Genetics and Cytogenetics</i> , 1996, 89, 7-13.	1.0	45
189	MicroRNA-135b regulates ER $\alpha$ , AR and HIF1AN and affects breast and prostate cancer cell growth. <i>Molecular Oncology</i> , 2015, 9, 1287-1300.	4.6	45
190	Cigarette Smoking Alters Sympathoadrenal Regulation by Decreasing the Density of $\beta$ 2-Adrenoceptors. A Study of Monitored Smoking Cessation. <i>Journal of Cardiovascular Pharmacology</i> , 1991, 17, 923-928.	1.9	44
191	Extrachromosomal gene amplification in acute myeloid leukemia; Characterization by metaphase analysis, comparative genomic hybridization, and semi-quantitative PCR. <i>Genes Chromosomes and Cancer</i> , 1993, 8, 185-189.	2.8	44
192	Title is missing!. <i>Machine Learning</i> , 2003, 52, 45-66.	5.4	44
193	Analysis of Kinase Gene Expression Patterns across 5681 Human Tissue Samples Reveals Functional Genomic Taxonomy of the Kinome. <i>PLoS ONE</i> , 2010, 5, e15068.	2.5	44
194	Integrative Functional Genomics Analysis of Sustained Polyploidy Phenotypes in Breast Cancer Cells Identifies an Oncogenic Profile for GINS2. <i>Neoplasia</i> , 2010, 12, 877-884.	5.3	44
195	Lysophosphatidic acid and sphingosine-1-phosphate promote morphogenesis and block invasion of prostate cancer cells in three-dimensional organotypic models. <i>Oncogene</i> , 2012, 31, 2075-2089.	5.9	44
196	Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML. <i>Leukemia</i> , 2017, 31, 1187-1195.	7.2	44
197	Detection of retinoblastoma gene copy number in metaphase chromosomes and interphase nuclei by fluorescence in situ hybridization. <i>Cytogenetic and Genome Research</i> , 1992, 60, 190-193.	1.1	43
198	Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL. <i>Leukemia</i> , 2019, 33, 1570-1582.	7.2	43

#	ARTICLE	IF	CITATIONS
199	Functional Profiling of Precursor MicroRNAs Identifies MicroRNAs Essential for Glioma Proliferation. <i>PLoS ONE</i> , 2013, 8, e60930.	2.5	43
200	Relatives of prostate cancer patients have an increased risk of prostate and stomach cancers: a population-based, cancer registry study in Finland. <i>Cancer Causes and Control</i> , 2001, 12, 223-230.	1.8	42
201	Prognostic Impact of ANX7-GTPase in Metastatic and HER2-Negative Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2004, 10, 2344-2350.	7.0	42
202	Critical Comparison of Virtual Screening Methods against the MUV Data Set. <i>Journal of Chemical Information and Modeling</i> , 2009, 49, 2168-2178.	5.4	42
203	The miR-15a-16 locus is homozygously deleted in a subset of prostate cancers. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 499-509.	2.8	42
204	Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia. <i>Leukemia</i> , 2017, 31, 51-57.	7.2	42
205	The impact of RNA sequence library construction protocols on transcriptomic profiling of leukemia. <i>BMC Genomics</i> , 2017, 18, 629.	2.8	42
206	Clinical and functional target validation using tissue and cell microarrays. <i>Current Opinion in Chemical Biology</i> , 2002, 6, 97-101.	6.1	41
207	BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition. <i>European Journal of Human Genetics</i> , 2006, 14, 167-172.	2.8	41
208	Interaction with ErbB4 Promotes Hypoxia-inducible Factor-1 $\alpha$ Signaling. <i>Journal of Biological Chemistry</i> , 2012, 287, 9659-9671.	3.4	40
209	Prognostic, predictive, and pharmacogenomic assessments of <i>CDX2</i> refine stratification of colorectal cancer. <i>Molecular Oncology</i> , 2018, 12, 1639-1655.	4.6	40
210	A new look towards BAC-based array CGH through a comprehensive comparison with oligo-based array CGH. <i>BMC Genomics</i> , 2007, 8, 84.	2.8	39
211	Germline TP53 alterations in Finnish breast cancer families are rare and occur at conserved mutation-prone sites. <i>British Journal of Cancer</i> , 2001, 84, 116-119.	6.4	38
212	A functional genetic screen reveals new regulators of $\beta$ 1-integrin activity. <i>Journal of Cell Science</i> , 2012, 125, 649-661.	2.0	38
213	Akt Inhibitor MK2206 Prevents Influenza pH1N1 Virus Infection <i>In Vitro</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3689-3696.	3.2	38
214	T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma. <i>Haematologica</i> , 2019, 104, 338-346.	3.5	38
215	Glucocorticoids induce differentiation and chemoresistance in ovarian cancer by promoting ROR1-mediated stemness. <i>Cell Death and Disease</i> , 2020, 11, 790.	6.3	38
216	Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival. <i>Blood Advances</i> , 2020, 4, 274-286.	5.2	38

#	ARTICLE	IF	CITATIONS
217	Lipoprotein uptake in primary cell cultures of rabbit atherosclerotic lesions. <i>Atherosclerosis</i> , 1988, 69, 257-268.	0.8	35
218	Physical Mapping of Chromosome 17 Cosmids by Fluorescence in Situ Hybridization and Digital Image Analysis. <i>Genomics</i> , 1994, 20, 125-128.	2.9	35
219	Comparison of Affymetrix data normalization methods using 6,926 experiments across five array generations. <i>BMC Bioinformatics</i> , 2009, 10, S24.	2.6	35
220	Heparin-like Polysaccharides Reduce Osteolytic Bone Destruction and Tumor Growth in a Mouse Model of Breast Cancer Bone Metastasis. <i>Molecular Cancer Research</i> , 2012, 10, 597-604.	3.4	35
221	miR-183 in Prostate Cancer Cells Positively Regulates Synthesis and Serum Levels of Prostate-specific Antigen. <i>European Urology</i> , 2015, 68, 581-588.	1.9	35
222	Immunoelectron-microscopic localization of a proliferation-associated antigen Ki-67 in MCF-7 cells. <i>The Histochemical Journal</i> , 1990, 22, 498-506.	0.6	34
223	Androgen Receptor Gene Alterations in Finnish Male Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2003, 77, 167-170.	2.5	34
224	Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis. <i>Oncogene</i> , 2014, 33, 3538-3549.	5.9	34
225	Automated peak detection and cell cycle analysis of flow cytometric DNA histograms. <i>Cytometry</i> , 1994, 16, 250-255.	1.8	33
226	Mechanically stretched chromosomes as targets for high-resolution FISH mapping. <i>Genome Research</i> , 1995, 5, 13-20.	5.5	33
227	BRCA2 Mutations in 154 Finnish Male Breast Cancer Patients. <i>Neoplasia</i> , 2004, 6, 541-545.	5.3	33
228	Mammary-Derived Growth Inhibitor Alters Traffic of EGFR and Induces a Novel Form of Cetuximab Resistance. <i>Clinical Cancer Research</i> , 2009, 15, 6570-6581.	7.0	33
229	HES6 gene is selectively overexpressed in glioma and represents an important transcriptional regulator of glioma proliferation. <i>Oncogene</i> , 2012, 31, 1299-1310.	5.9	33
230	Identification of structural features in chemicals associated with cancer drug response: a systematic data-driven analysis. <i>Bioinformatics</i> , 2014, 30, i497-i504.	4.1	33
231	Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2060-2071.	4.1	33
232	Fiber-FISH: experiences and a refined protocol. <i>Genetic Analysis, Techniques and Applications</i> , 1996, 12, 179-184.	1.5	32
233	ANX7 as a Bio-Marker in Prostate and Breast Cancer Progression. <i>Disease Markers</i> , 2001, 17, 115-120.	1.3	32
234	15 $\alpha$ -Hydroxyprostaglandin dehydrogenase associates with poor prognosis in breast cancer, induces epithelial-mesenchymal transition, and promotes cell migration in cultured breast cancer cells. <i>Journal of Pathology</i> , 2012, 226, 674-686.	4.5	32

#	ARTICLE	IF	CITATIONS
235	Impact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose-response data. <i>Bioinformatics</i> , 2015, 31, 3815-3821.	4.1	31
236	A major locus for hereditary prostate cancer in Finland: localization by linkage disequilibrium of a haplotype in the HPCX region. <i>Human Genetics</i> , 2005, 117, 307-316.	3.8	30
237	Interactions between Notch- and hypoxia-induced transcriptomes in embryonic stem cells. <i>Experimental Cell Research</i> , 2010, 316, 1610-1624.	2.6	30
238	Integrative genomic, transcriptomic, and RNAi analysis indicates a potential oncogenic role for FAM110B in castration-resistant prostate cancer. <i>Prostate</i> , 2012, 72, 789-802.	2.3	30
239	Oncogenic Herpesvirus Utilizes Stress-Induced Cell Cycle Checkpoints for Efficient Lytic Replication. <i>PLoS Pathogens</i> , 2016, 12, e1005424.	4.7	30
240	Genetic changes in familial prostate cancer by comparative genomic hybridization. <i>Prostate</i> , 2001, 46, 233-239.	2.3	29
241	ITGB1-dependent upregulation of Caveolin-1 switches TGF $\beta$ 2 signalling from tumour-suppressive to oncogenic in prostate cancer. <i>Scientific Reports</i> , 2018, 8, 2338.	3.3	29
242	Clonal heterogeneity influences drug responsiveness in renal cancer assessed by <i>ex vivo</i> drug testing of multiple patient-derived cancer cells. <i>International Journal of Cancer</i> , 2019, 144, 1356-1366.	5.1	29
243	GTI: A Novel Algorithm for Identifying Outlier Gene Expression Profiles from Integrated Microarray Datasets. <i>PLoS ONE</i> , 2011, 6, e17259.	2.5	29
244	Genome-wide scanning for linkage in Finnish breast cancer families. <i>European Journal of Human Genetics</i> , 2004, 12, 98-104.	2.8	27
245	Plasticity of Blood- and Lymphatic Endothelial Cells and Marker Identification. <i>PLoS ONE</i> , 2013, 8, e74293.	2.5	26
246	Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells. <i>Gynecologic Oncology</i> , 2017, 144, 621-630.	1.4	26
247	Serum CA 125 in acute pelvic inflammatory disease. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1989, 96, 574-579.	2.3	25
248	Molecular cytogenetics: Diagnosis and prognostic assessment. <i>Current Opinion in Biotechnology</i> , 1992, 3, 623-631.	6.6	25
249	Hereditary prostate cancer in Finland: fine-mapping validates 3p26 as a major predisposition locus. <i>Human Genetics</i> , 2005, 116, 43-50.	3.8	25
250	Human Protein Atlas charts a diverse terrain. <i>Trends in Biotechnology</i> , 2006, 24, 195-197.	9.3	25
251	Plasminogen activator urokinase expression reveals TRAIL responsiveness and supports fractional survival of cancer cells. <i>Cell Death and Disease</i> , 2014, 5, e1043-e1043.	6.3	25
252	Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma. <i>Blood Advances</i> , 2017, 1, 2257-2268.	5.2	25



#	ARTICLE	IF	CITATIONS
253	Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML. <i>Leukemia</i> , 2019, 33, 2548-2553.	7.2	25
254	DNA Ploidy Level and Cell Cycle Distribution in Ovarian Cancer. <i>International Journal of Gynecological Pathology</i> , 1988, 7, 1-11.	1.4	24
255	c-erbB-2 in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridization. <i>British Journal of Cancer</i> , 1996, 73, 620-623.	6.4	24
256	Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas. <i>British Journal of Cancer</i> , 2019, 120, 435-443.	6.4	24
257	Chemical Biology Drug Sensitivity Screen Identifies Sunitinib as Synergistic Agent with Disulfiram in Prostate Cancer Cells. <i>PLoS ONE</i> , 2012, 7, e51470.	2.5	24
258	Molecular Cytogenetics of Human Breast Cancer. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 1994, 59, 645-652.	1.1	23
259	Haplotype analysis in Icelandic and Finnish BRCA2 999del5 breast cancer families. <i>European Journal of Human Genetics</i> , 2001, 9, 773-779.	2.8	23
260	Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response. <i>Breast Cancer: Targets and Therapy</i> , 2017, Volume 9, 185-198.	1.8	23
261	Fibroblast as a critical stromal cell type determining prognosis in prostate cancer. <i>Prostate</i> , 2019, 79, 1505-1513.	2.3	23
262	Building an international consortium for tracking coronavirus health status. <i>Nature Medicine</i> , 2020, 26, 1161-1165.	30.7	23
263	From chromosomal alterations to target genes for therapy: integrating cytogenetic and functional genomic views of the breast cancer genome. <i>Seminars in Cancer Biology</i> , 2001, 11, 395-401.	9.6	22
264	BRCA1 and BRCA2 mutations have no major role in predisposition to prostate cancer in Finland. <i>Journal of Medical Genetics</i> , 2003, 40, 98e-98.	3.2	22
265	DNA flow cytometric analysis indicates that many breast cancers detected in the first round of mammographic screening have a low malignant potential. <i>International Journal of Cancer</i> , 1988, 42, 697-702.	5.1	21
266	Inter-laboratory comparison of DNA flow cytometric results from paraffin-embedded breast carcinomas. <i>Breast Cancer Research and Treatment</i> , 1990, 17, 59-61.	2.5	21
267	A strategy for identifying putative causes of gene expression variation in human cancers. <i>Journal of the Franklin Institute</i> , 2004, 341, 77-88.	3.4	21
268	Evaluation of the role of Finnish ataxia-telangiectasia mutations in hereditary predisposition to breast cancer. <i>Carcinogenesis</i> , 2006, 28, 1040-1045.	2.8	21
269	Morphological spot counting from stacked images for automated analysis of gene copy numbers by fluorescence in situ hybridization. <i>Journal of Biomedical Optics</i> , 2002, 7, 109.	2.6	20
270	Medicine: Profile of a tumour. <i>Nature</i> , 2004, 428, 379-382.	27.8	20

#	ARTICLE	IF	CITATIONS
271	<i>PLA2G7</i> associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cells. <i>Journal of Pathology: Clinical Research</i> , 2017, 3, 123-138.	3.0	20
272	Combined epithelial marker analysis of tumour budding in stage II colorectal cancer. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 63-78.	3.0	20
273	Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell lines. <i>Nature Communications</i> , 2022, 13, 1691.	12.8	20
274	The human gene for xanthine dehydrogenase (XDH) is localized on chromosome band 2p22. <i>Cytogenetic and Genome Research</i> , 1995, 68, 61-63.	1.1	19
275	Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing. <i>Blood Cancer Journal</i> , 2015, 5, e309-e309.	6.2	19
276	Relevance Rank Platform (RRP) for Functional Filtering of High Content Protein-Protein Interaction Data*. <i>Molecular and Cellular Proteomics</i> , 2015, 14, 3274-3283.	3.8	19
277	Spatial aspects of oncogenic signalling determine the response to combination therapy in slice explants from <i>Kras</i> -driven lung tumours. <i>Journal of Pathology</i> , 2018, 245, 101-113.	4.5	19
278	Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types. <i>Haematologica</i> , 2020, 105, 1527-1538.	3.5	19
279	Growth properties and composition of cytoskeletal and cytocontractile proteins in aortic cells isolated and cultured from normal and atherosclerotic rabbits. <i>Atherosclerosis</i> , 1984, 52, 13-26.	0.8	18
280	A novel transcript, <i>VNN1-AB</i> , as a biomarker for colorectal cancer. <i>International Journal of Cancer</i> , 2014, 135, 2077-2084.	5.1	18
281	Characterization of farnesyl diphosphate farnesyl transferase 1 ( <i>FDFT1</i> ) expression in cancer. <i>Personalized Medicine</i> , 2019, 16, 51-65.	1.5	17
282	Androgen receptor gene amplification: A novel molecular mechanism for endocrine therapy resistance in human prostate cancer. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1996, 56, 57-63.	1.2	17
283	Comprehensive data-driven analysis of the impact of chemoinformatic structure on the genome-wide biological response profiles of cancer cells to 1159 drugs. <i>BMC Bioinformatics</i> , 2012, 13, 112.	2.6	16
284	Intrinsic resistance to PIM kinase inhibition in AML through p38-mediated feedback activation of mTOR signaling. <i>Oncotarget</i> , 2016, 7, 37407-37419.	1.8	16
285	Simulation Toolbox for 3D-FISH Spot-Counting Algorithms. <i>Real Time Imaging</i> , 2002, 8, 203-212.	1.6	15
286	A loss-of-function genetic screening identifies novel mediators of thyroid cancer cell viability. <i>Oncotarget</i> , 2016, 7, 28510-28522.	1.8	15
287	Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors. <i>Molecular Oncology</i> , 2017, 11, 1156-1171.	4.6	15
288	Flow Cytometric Analysis of Tumour dna Profile Related to Response to Radiotherapy and Survival in Inoperable Lung Cancer. <i>Acta Oncologica</i> , 1990, 29, 983-988.	1.8	14

#	ARTICLE	IF	CITATIONS
289	Anagrelide for Gastrointestinal Stromal Tumor. <i>Clinical Cancer Research</i> , 2019, 25, 1676-1687.	7.0	14
290	Nuclear DNA content of non-endemic Burkitt's lymphoma.. <i>Journal of Clinical Pathology</i> , 1987, 40, 1201-1205.	2.0	13
291	A Decade of Cancer Gene Profiling: From Molecular Portraits to Molecular Function. <i>Methods in Molecular Biology</i> , 2009, 576, 61-87.	0.9	13
292	Clinical relevance of integrin alpha 4 in gastrointestinal stromal tumours. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 2220-2230.	3.6	13
293	Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors. <i>Oncotarget</i> , 2017, 8, 22606-22615.	1.8	13
294	Prognostic Assessment in Stage I Ovarian Cancer Using a Discriminant Analysis with Clinicopathological and DNA Flow Cytometric Data. <i>Gynecologic and Obstetric Investigation</i> , 1989, 27, 213-216.	1.6	12
295	Classification of unknown primary tumors with a data-driven method based on a large microarray reference database. <i>Genome Medicine</i> , 2011, 3, 63.	8.2	12
296	ARLTS1 and Prostate Cancer Risk - Analysis of Expression and Regulation. <i>PLoS ONE</i> , 2013, 8, e72040.	2.5	12
297	Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia. <i>Npj Precision Oncology</i> , 2021, 5, 71.	5.4	12
298	Molecular cytogenetic mapping of 24 CEPH YACs and 24 gene-specific large insert probes to chromosome 17. <i>Cytogenetic and Genome Research</i> , 1998, 82, 189-191.	1.1	11
299	Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer. <i>BMC Cancer</i> , 2016, 16, 378.	2.6	11
300	Monitoring therapy responses at the leukemic subclone level by ultra-deep amplicon resequencing in acute myeloid leukemia. <i>Leukemia</i> , 2017, 31, 1048-1058.	7.2	11
301	Correlation between Serum Tumor Marker Levels and Tumor Proliferation in Small Cell Lung Cancer. <i>Tumor Biology</i> , 1988, 9, 287-292.	1.8	10
302	Prognostic value of cells with more than 5c DNA content in node-negative breast cancer as determined by image cytometry from tissue sections. <i>Human Pathology</i> , 1993, 24, 1348-1353.	2.0	10
303	Androgen receptor-interacting protein <sc>HSPBAP1</sc> facilitates growth of prostate cancer cells in androgen-deficient conditions. <i>International Journal of Cancer</i> , 2015, 136, 2535-2545.	5.1	10
304	Primary invasive and in situ vaginal carcinoma. Flow cytometric analysis of DNA aneuploidy and cell proliferation from archival paraffin-embedded tissue. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 1989, 32, 247-251.	1.1	9
305	Low biological aggressiveness of screen-detected lung cancers may indicate over-diagnosis. , 1996, 66, 6-10.		9
306	Evaluation of camera requirements for comparative genomic hybridization. , 1996, 25, 394-398.		9

#	ARTICLE	IF	CITATIONS
307	Comparison of structure fingerprint and molecular interaction field based methods in explaining biological similarity of small molecules in cell-based screens. <i>Journal of Computer-Aided Molecular Design</i> , 2009, 23, 227-239.	2.9	9
308	On the organization of bioinformatics core services in biology-based research institutes. <i>Bioinformatics</i> , 2011, 27, 1345-1345.	4.1	9
309	The transcriptome-wide landscape of molecular subtype-specific <scp>mRNA</scp> expression profiles in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 580-588.	4.1	9
310	STRN-ALK rearranged pediatric malignant peritoneal mesothelioma – Functional testing of 527 cancer drugs in patient-derived cancer cells. <i>Translational Oncology</i> , 2021, 14, 101027.	3.7	9
311	Systemic Analysis of Gene Expression Profiles Identifies ErbB3 as a Potential Drug Target in Pediatric Alveolar Rhabdomyosarcoma. <i>PLoS ONE</i> , 2012, 7, e50819.	2.5	9
312	Elevated serum hmfg antigen levels in breast and ovarian cancer patients measured with a sandwich elisa. <i>International Journal of Cancer</i> , 1988, 41, 28-33.	5.1	8
313	Data integration from two microarray platforms identifies bi-allelic genetic inactivation of RIC8A in a breast cancer cell line. <i>BMC Medical Genomics</i> , 2009, 2, 26.	1.5	8
314	Contribution of ARLTS1 Cys148Arg (T442C) Variant with Prostate Cancer Risk and ARLTS1 Function in Prostate Cancer Cells. <i>PLoS ONE</i> , 2011, 6, e26595.	2.5	8
315	Genetic Risk Score for Serum 25-Hydroxyvitamin D Concentration Helps to Guide Personalized Vitamin D Supplementation in Healthy Finnish Adults. <i>Journal of Nutrition</i> , 2021, 151, 281-292.	2.9	8
316	Multomics and digital monitoring during lifestyle changes reveal independent dimensions of human biology and health. <i>Cell Systems</i> , 2022, 13, 241-255.e7.	6.2	8
317	Functional genomics and transcriptomics of prostate cancer: promises and limitations. <i>BJU International</i> , 2005, 96, 10-15.	2.5	7
318	The Porto European Cancer Research Summit 2021. <i>Molecular Oncology</i> , 2021, 15, 2507-2543.	4.6	7
319	NMD Microarray Analysis for Rapid Genome-Wide Screen of Mutated Genes in Cancer. <i>Analytical Cellular Pathology</i> , 2005, 27, 169-173.	1.4	7
320	High-throughput cell-based compound screen identifies pinosylvin methyl ether and tanshinone IIA as inhibitors of castration-resistant prostate cancer. <i>Journal of Molecular Biochemistry</i> , 2016, 5, 12-22.	0.1	7
321	Suppression of autologous mixed leukocyte reaction in type 1 diabetes mellitus by in vivo-activated T lymphocytes. <i>Clinical Immunology and Immunopathology</i> , 1989, 52, 406-413.	2.0	6
322	Nationwide cancer family ascertainment using Finnish cancer registry data on family names and places of birth for 35,761 prostate cancer patients. <i>International Journal of Cancer</i> , 2000, 88, 307-312.	5.1	6
323	Epigenetics of prostate cancer and the prospect of identification of novel drug targets by RNAi screening of epigenetic enzymes. <i>Epigenomics</i> , 2010, 2, 683-689.	2.1	6
324	KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2780-2784.	7.2	6

#	ARTICLE	IF	CITATIONS
325	Recurrent Missense Mutations in the STAT3 Gene in LGL Leukemia Provide Insights to Pathogenetic Mechanisms and Suggest Potential Diagnostic and Therapeutic Applications. <i>Blood</i> , 2011, 118, 936-936.	1.4	6
326	FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML. <i>Scientific Reports</i> , 2021, 11, 23565.	3.3	6
327	Analysis of DNA synthesis in herpes simplex virus infected cells by dual parameter flow cytometry. <i>Archives of Virology</i> , 1989, 107, 215-223.	2.1	5
328	Comparative genomic hybridization gaining in popularity. <i>Trends in Genetics</i> , 1996, 12, 237-238.	6.7	5
329	Integrated breast cancer genomics. <i>Cancer Cell</i> , 2006, 10, 453-454.	16.8	5
330	Cancer Genomes. <i>Clinical Chemistry</i> , 2010, 56, 1660-1664.	3.2	5
331	Alignment of gene expression profiles from test samples against a reference database: New method for context-specific interpretation of microarray data. <i>BioData Mining</i> , 2011, 4, 5.	4.0	5
332	Aneuploidy facilitates oncogenic transformation via specific genetic alterations, including Twist2 upregulation. <i>Carcinogenesis</i> , 2013, 34, 2000-2009.	2.8	5
333	Genetic Instability of Influenza pH1N1 Viruses. <i>Genome Announcements</i> , 2014, 2, .	0.8	5
334	Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types. <i>Blood</i> , 2018, 132, 264-264.	1.4	5
335	Novel Activating STAT5B Mutations As Drivers Of T-ALL. <i>Blood</i> , 2013, 122, 3863-3863.	1.4	5
336	Linking chromosomal clues. <i>Nature Genetics</i> , 1997, 15, 5-6.	21.4	4
337	High tumor cell platelet-derived growth factor receptor beta expression is associated with shorter survival in malignant pleural epithelioid mesothelioma. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 482-494.	3.0	4
338	High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma. <i>Translational Oncology</i> , 2022, 15, 101290.	3.7	4
339	E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models. <i>Molecular Oncology</i> , 2022, 16, 2312-2329.	4.6	4
340	KRAS Oncogene Rearrangements and Gene Fusions: Unexpected Rare Encounters in Late-Stage Prostate Cancers: Table 1.. <i>Cancer Discovery</i> , 2011, 1, 12-13.	9.4	3
341	Circulating tumor DNA in early-stage breast cancer: personalized biomarkers for occult metastatic disease and risk of relapse?. <i>EMBO Molecular Medicine</i> , 2015, 7, 994-995.	6.9	3
342	Abstract 3977: Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. , 2011, , .		3

#	ARTICLE	IF	CITATIONS
343	Abstract 3175: Genomic and transcriptomic data integration in chronic myelomonocytic leukemia reveals a novel fusion gene involving onco-miR-125b-2. , 2012, , .		3
344	The Use of RNA Sequencing to Identify Disease-Specific Gene Expression Signatures and Critical Regulatory Networks Across Hematologic Malignancies. Blood, 2014, 124, 2203-2203.	1.4	3
345	Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma. Blood, 2014, 124, 2046-2046.	1.4	3
346	P26. MicroRNA expression profiling and functional screening in bone metastatic breast cancer cells. Cancer Treatment Reviews, 2008, 34, 22.	7.7	2
347	Monensin Induced Oxidative Stress Reduces Prostate Cancer Cell Migration and Cancer Stem Cell Population. , 0, , .		2
348	Predictive Response Biomarkers for BET Inhibitors in AML. Blood, 2018, 132, 2749-2749.	1.4	2
349	Discovery of STAT5b Mutations and Small Subclones of STAT3 Mutations in Large Granular Lymphocytic (LGL) Leukemia. Blood, 2012, 120, 871-871.	1.4	2
350	Molecular Cytogenetics of Solid Tumor Progression. , 1996, , 68-78.		2
351	Stromal FAP Expression is Associated with MRI Visibility and Patient Survival in Prostate Cancer. Cancer Research Communications, 2022, 2, 172-181.	1.7	2
352	RESPONSE: Re: Population-Based Study of BRCA1 and BRCA2 Mutations in 1035 Unselected Finnish Breast Cancer Patients. Journal of the National Cancer Institute, 2001, 93, 153-154.	6.3	1
353	Dissection of molecular pathways of cancer by high-throughput biochip technologies and RNA interference. Breast Cancer Research, 2005, 7, 1.	5.0	1
354	826: Primary T-prolymphocytic leukemia (T-PLL) cells are sensitive to BCL-2 and HDAC inhibitors: Results from high-throughput ex vivo drug testing. European Journal of Cancer, 2014, 50, S200.	2.8	1
355	Abstract 52: A new method to interpret gene expression microarray data for individual tumors by profile alignment against a reference dataset of 10,000 samples. , 2011, , .		1
356	Abstract 2984: A comprehensive bioinformatic analysis of the representativity of 460 cancer cell lines as model systems for 88 different clinical cancer types. , 2012, , .		1
357	Abstract 4580: Personalized treatment selection for therapy-resistant AML by integrating ex-vivo drug sensitivity and resistance testing (DSRT) as well as serial genomic, transcriptomic and phosphoproteomic profiling. , 2012, , .		1
358	Abstract 5067: Exome sequencing reveals both DNA sequence and copy number changes in AML: Potential driver changes and mechanisms of drug resistance revealed from serial samples from the same patients. , 2012, , .		1
359	Comparative Analysis of Independent Ex Vivo functional Drug Screens Identifies Predictive Biomarkers of BCL-2 Inhibitor Response in AML. Blood, 2018, 132, 2763-2763.	1.4	1
360	High-Throughput Functional Ex-Vivo Drug Testing and Multi-Omics Profiling in Patients with Acute Myeloid Leukemia. Blood, 2019, 134, 4641-4641.	1.4	1

#	ARTICLE	IF	CITATIONS
361	Landscape of Mutations in Relapsed Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 2367-2367.	1.4	1
362	Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles. <i>Blood</i> , 2017, 130, 854-854.	1.4	1
363	Abstract 845: Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis. , 2011, , .		1
364	High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options with Targeted Drugs in Subgroups of Relapsed Chemorefractory AML. <i>Blood</i> , 2012, 120, 288-288.	1.4	1
365	AML Specific Targeted Drugs Identified By Drug Sensitivity and Resistance Testing: Comparison of Ex Vivo Patient Cells with in Vitro Cell Lines. <i>Blood</i> , 2014, 124, 2163-2163.	1.4	1
366	Abstract 3746: Novel therapeutic possibilities for chemorefractory ovarian cancer patients identified by functional ex vivo drug sensitivity testing of primary cells from ascites. , 2015, , .		1
367	Abstract 2378: Responses of AML patients to tailored drug regimens: monitoring cancer subclones by ultra-deep resequencing. , 2016, , .		1
368	Abstract 5732: PI3K/Akt activity regulates androgen receptor expression and predicts poor clinical outcome in non-metastatic hormone-naïve prostate cancer. , 2017, , .		1
369	Abstract 5029: Precision cancer medicine based on 3D drug profiling of patient-derived cancer cell spheroid models. , 2018, , .		1
370	Herpes virus specified early proteins induce cellular DNA synthesis in virus infected cervical cancer cells. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1987, 23, 1771.	0.7	0
371	Nuclear DNA content characteristics of 129 high grade malignancy non-Hodgkin lymphomas. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1987, 23, 1775.	0.7	0
372	Prognostic impact of DNA-ploidy and S-phase fraction. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1987, 23, 1765.	0.7	0
373	Molecular genetics of human prostate cancer. <i>Current Opinion in Urology</i> , 1997, 7, 259-262.	1.8	0
374	Claes Lundsteenâ€™in Memoriam. <i>European Journal of Human Genetics</i> , 2004, 12, 603-603.	2.8	0
375	Application of Microarray Technologies for Translational Genomics. <i>Biological and Medical Physics Series</i> , 2005, , 361-374.	0.4	0
376	The weibull distribution based normalization method for affymetrix gene expression microarray data. , 2006, , .		0
377	Cancer genome analysis: a landscape seen from many angles. <i>Drug Discovery Today Disease Mechanisms</i> , 2007, 4, 269-276.	0.8	0
378	558 Systematic functional analysis of microRNAs by transfection of 1129 miRNAs into prostate cancer cells. <i>European Journal of Cancer, Supplement</i> , 2010, 8, 177.	2.2	0



#	ARTICLE	IF	CITATIONS
379	338 The HER2 Amplicon Includes Several Genes Required for the Growth and Survival of HER2 Positive Breast Cancer Cells. <i>European Journal of Cancer</i> , 2012, 48, S82-S83.	2.8	0
380	589 Precursor MicroRNA Functional Profiling Identifies MicroRNAs Essential for Glioblastoma Proliferation. <i>European Journal of Cancer</i> , 2012, 48, S140.	2.8	0
381	681 Aneuploidy Facilitates Oncogenic Transformation Via Specific Genetic Alterations. <i>European Journal of Cancer</i> , 2012, 48, S161.	2.8	0
382	825 Exome Sequencing of T-LGL Leukemia Patient Revealed ANGPT2 as a Possible Mutational Target. <i>European Journal of Cancer</i> , 2012, 48, S198.	2.8	0
383	461 Identification of Personalized Therapeutic Strategies and Associated Biomarkers in Adult Acute Myeloid Leukemia Using a Functional Drug Sensitivity and Resistance Testing Platform. <i>European Journal of Cancer</i> , 2012, 48, 142-143.	2.8	0
384	684: Helsinki Urological Biobank (HUB): A new-generation integrated biobank for facilitating precision medicine and translational research in urological cancers. <i>European Journal of Cancer</i> , 2014, 50, S164.	2.8	0
385	273: Androgen receptor interacting protein HSPBAP1 facilitates growth of prostate cancer cells in androgen-deficient conditions. <i>European Journal of Cancer</i> , 2014, 50, S64.	2.8	0
386	Stromal-Derived Factors Modulate Ex Vivo Drug Responses of Primary Acute Myeloid Leukemia Cells. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S8-S9.	0.4	0
387	Case studies investigating genetic heterogeneity between anatomically distinct bone marrow compartments in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 3002-3005.	1.3	0
388	Abstract 1953: Functional identification of microRNA targets by integrated proteomics and microarray profiling: miR-193b in breast cancer. , 2010, , .		0
389	Abstract 2072: Systematic functional analysis of microRNAs by transfection of 1129 miRNAs into prostate cancer cells. , 2010, , .		0
390	Abstract 3800: HES6 gene is a strong glioma biomarker and a key transcriptional regulator needed for cancer cell growth. , 2011, , .		0
391	Abstract 2597: PLA2G7 associates with aggressive prostate cancer in vivo and regulates prostate cancer cell migration and adhesion in vitro. , 2011, , .		0
392	Abstract 4836: In vitro drug sensitivity testing along with full genome and transcriptome sequencing and phosphoproteomics: Comprehensive "next-generation" molecular oncology portrait of a sarcoma for facilitating treatment decisions. , 2011, , .		0
393	Abstract 4850: Paired-end RNA-sequencing based identification of 24 novel fusion genes in breast cancer. , 2011, , .		0
394	Abstract 4023: ARID1A is a candidate tumor suppressor gene in breast cancer. , 2011, , .		0
395	Development of a Cancer Pharmacopeia-Wide Ex-Vivo Drug Sensitivity and Resistance Testing (DSRT) Platform: Identification of MEK and mTOR As Patient-Specific Molecular Drivers of Adult AML and Potent Therapeutic Combinations with Dasatinib. <i>Blood</i> , 2011, 118, 2487-2487.	1.4	0
396	Abstract 895: Quantitative drug sensitivity and resistance testing (DSRT) of primary ex vivo AML blasts highlights mTOR and MEK as potential key molecular driver signals of therapeutic significance. , 2012, , .		0

#	ARTICLE	IF	CITATIONS
397	Abstract 3188: Development of a cancer pharmacopeia-wide ex-vivo drug sensitivity and resistance testing (DSRT) platform for AML: Towards individually optimized therapy and improved understanding of drug resistance patterns. , 2012, , .		0
398	Abstract 334: Identification of novel regulatory genes controlling epithelial to mesenchymal transition in cultured breast cancer cells. , 2012, , .		0
399	Somatic PTPRT and ANGPT2 Mutations in Large Granulocyte Leukemia. Blood, 2012, 120, 1302-1302.	1.4	0
400	Abstract 2107: Identification of alternative compounds by drug screening of HER2 positive breast cancer cell lines.. , 2013, , .		0
401	Abstract 65: Comprehensive ex vivo drug sensitivity testing combined with in depth molecular profiling of AML patients cells provides individualized treatment strategies and reveals mechanisms of drug resistance.. , 2013, , .		0
402	Abstract 5588: Functional drug sensitivity and resistance profiling of AML patient cells defines a disease-specific combination of druggable signal addictions.. , 2013, , .		0
403	Abstract 721: Multiplexed systems pathology for in-depth analysis of the tumor microenvironment: a strong correlation between pAkt and androgen receptor in the epithelial component of prostate cancer.. , 2013, , .		0
404	Abstract A34: Development of a drug sensitivity testing pipeline towards the establishment of precision medicine for ovarian cancer. , 2013, , .		0
405	Stromal Cell Supported High-Throughput Drug Testing Of Primary Leukemia Cells For Comprehensive Assessment Of Sensitivity To Novel Therapies. Blood, 2013, 122, 1668-1668.	1.4	0
406	Primary T-Prolymphocytic Leukemia (T-PLL) Cells Are Sensitive To BCL-2 and HDAC Inhibitors: Results From High-Throughput Ex Vivo Drug Testing. Blood, 2013, 122, 3828-3828.	1.4	0
407	Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling. Blood, 2013, 122, 482-482.	1.4	0
408	High-Throughput Drug Sensitivity and Resistance Testing (DSRT) Platform Reveals Novel Candidate Drugs For Advanced Phase BCR-ABL1-Positive Leukemia. Blood, 2013, 122, 2719-2719.	1.4	0
409	Abstract 982: Analysis of clonal evolution of leukemia in vivo following novel targeted treatments. , 2014, , .		0
410	Abstract 5384: Systematic high-throughput drug sensitivity and resistance testing (DSRT) of ovarian cancer cell lines indicates novel therapeutic possibilities with existing and emerging drugs. , 2014, , .		0
411	Abstract 4184: Drug set enrichment analysis : A computational approach to identify functional drug sets. , 2014, , .		0
412	Discovery of Novel Drug Sensitivities in T-Prolymphocytic Leukemia (T-PLL) By High-Throughput Ex Vivo Drug Testing and Genetic Profiling. Blood, 2014, 124, 917-917.	1.4	0
413	Stroma-Derived Factors Significantly Impact the Drug Response Profiles of Patient-Derived Primary AML Cells: Implications for Drug Sensitivity Testing. Blood, 2014, 124, 3505-3505.	1.4	0
414	Analysis of Clonal Evolution in Chemorefractory Acute Myeloid Leukemia from Diagnosis to Relapse. Blood, 2014, 124, 1022-1022.	1.4	0

#	ARTICLE	IF	CITATIONS
415	A Profound Biological Difference of Chronic and Blast Phase Chronic Myeloid Leukemia in Ex Vivo Drug Responses. Blood, 2014, 124, 3139-3139.	1.4	0
416	Abstract POSTER-TECH-1111: High-throughput drug sensitivity and resistance testing of ovarian cancer cell lines provides useful strategy for assessing drug repositioning and therapeutic possibilities of emerging drugs. , 2015, , .		0
417	Abstract 1698: Systems pathology for characterization of cancer model systems in a multicenter IMI-PREDECT project. , 2015, , .		0
418	Abstract 676: Axitinib targets gatekeeper-mutant BCR-ABL1(T315I)-driven leukemia in a distinct and selective fashion. , 2015, , .		0
419	Abstract 207: Caveolin-1 drives oncogenic TGF $\beta$ 2 effects in prostate cancer: in vitro mechanistic insights integrated with systems pathology visualization in primary tumor samples. , 2015, , .		0
420	BCL2-Inhibitors Target a Major Group of Newly-Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia Ex Vivo. Blood, 2015, 126, 2462-2462.	1.4	0
421	JAK1/2 and BCL2 Inhibitors Synergize to Counter-Act Bone Marrow Stromal Cell-Induced Protection of AML. Blood, 2015, 126, 867-867.	1.4	0
422	Novel drug discovery by pharmacogenomic profiling of 36 colorectal cancer cell lines.. Journal of Clinical Oncology, 2016, 34, 604-604.	1.6	0
423	Abstract 2935: Systematic drug testing and RNA-sequencing of tamoxifen resistant breast cancer cell lines. , 2016, , .		0
424	Abstract 1517: Impact of poly-A and ribo-depletion RNA-seq library construction protocols on transcriptomic analysis of samples from patients with haematological malignancies. , 2016, , .		0
425	Abstract 4679: Acquisition of cytarabine resistance leads to increased glucocorticoid sensitivity in AML. , 2016, , .		0
426	Immune Cell Profiling in CML Bone Marrow By Multiplex Immunohistochemistry. Blood, 2016, 128, 1897-1897.	1.4	0
427	Abstract 3122: Pharmacogenomic profiling to identify novel therapeutic strategies in colorectal cancer. , 2017, , .		0
428	Abstract 424: Landscape of somatic mutations in drug-resistant acute myeloid leukemia. , 2017, , .		0
429	Abstract 3854: Precision medicine approach: analysis of renal cancer patient-derived cells with phenomics, genomics and drug sensitivity profiling. , 2017, , .		0
430	Abstract 410: Identifying ovarian cancer specific targeted drugs using high-throughput drug sensitivity profiles of primary cancer cells. , 2017, , .		0
431	Abstract 5302: Phenotypic heterogeneity of patient-derived tumor cells visualized by unsupervised analysis in cell-based personalized drug testing. , 2018, , .		0
432	Abstract 3883: Gene expression predictsex vivodrug sensitivity in acute myeloid leukemia. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
433	Abstract 2199: Establishment and high-throughput drug testing of multiple patient-derived cells from each renal cancer; intratumor heterogeneity of drug response and implications for precision medicine. , 2018, , .		0
434	Abstract 3899: Discovery and clinical implementation of individualized therapies in acute myeloid leukemia based on ex vivo drug sensitivity testing and multi-omics profiling. , 2018, , .		0
435	Quantitative Multiplex Immunohistochemistry Identifies Immunosuppression in the AML Bone Marrow and NK-Cells As Prognostic Biomarker in Intermediate-Risk Patients. Blood, 2018, 132, 2774-2774.	1.4	0
436	Abstract 458: Precision systems medicine in acute myeloid leukemia: real-time translation of tailored therapeutic opportunities arising from ex-vivo drug sensitivity testing and molecular profiling. , 2019, , .		0
437	Abstract 2945: Clinical implementation of precision systems oncology in the treatment of ovarian cancer based on ex-vivo drug testing and molecular profiling. , 2019, , .		0
438	High-throughput RNAi screening identifies sensitizing targets to improve doxorubicin chemotherapy. Journal of Clinical Oncology, 2004, 22, 9543-9543.	1.6	0